Therefore, delineating the link between MT1H and HCC through modulating the Jak–STAT pathway at the crossroad of Akt/mTOR and Wnt/β-catenin pathways may provide new insights into a promising therapeutic approach. The gene discussed is AKT1; the disease is hepatocellular carcinoma.